0.00

100.00% -1.21

Rain Oncology Inc (RAIN)

Overview News Price History Option Chain Discussions Forecast

Rain Oncology Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0. It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.23 pivot point. If it approaches the $1.13 support level, significant changes may occur.

Previous Close:

$1.21

Open:

24h Volume:

Market Cap:

$44.03M

Revenue:

Net Income/Loss:

$-72.26M

P/E Ratio:

0.00

EPS:

-2.55

Net Cash Flow:

$-68.44M

1W Performance:

-100.00%

1M Performance:

-100.00%

6M Performance:

-100.00%

1Y Performance:

-100.00%

1D Range:

$0.00

52W Range:

$0.00

$10.51

Rain Oncology Inc Stock (RAIN) Company Profile

Name

Rain Oncology Inc

Sector

Healthcare (1198)

Industry

Biotechnology (688)

Phone

510 953 5559

Address

8000 Jarvis Avenue, Suite 204, Newark

Employee

Twitter

Next Earnings Date

2024-03-07

Latest SEC Filings

RAIN's Discussions on Twitter

Rain Oncology Inc Stock (RAIN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-21-23	Initiated	SVB Securities	Outperform
Jan-31-23	Resumed	ROTH Capital	Buy
Jan-23-23	Initiated	Mizuho	Buy
Sep-12-22	Initiated	H.C. Wainwright	Buy
Apr-01-22	Initiated	Oppenheimer	Outperform
Sep-14-21	Resumed	Goldman	Neutral
Jul-20-21	Initiated	Piper Sandler	Overweight
May-18-21	Initiated	Citigroup	Buy
May-18-21	Initiated	Goldman	Buy
May-18-21	Initiated	Guggenheim	Buy
May-18-21	Initiated	Piper Sandler	Overweight

View All

Rain Oncology Inc Stock (RAIN) Latest News

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

GlobeNewswire Inc.

Rain Oncology Inc Stock (RAIN) Financials Data

Rain Oncology Inc (RAIN) Net Income 2024

RAIN net income (TTM) was -$72.26 million for the quarter ending September 30, 2023, a -1.73% decrease year-over-year.

Rain Oncology Inc (RAIN) Cash Flow 2024

RAIN recorded a free cash flow (TTM) of -$68.44 million for the quarter ending September 30, 2023, a -14.71% decrease year-over-year.

Rain Oncology Inc (RAIN) Earnings per Share 2024

RAIN earnings per share (TTM) was -$2.06 for the quarter ending September 30, 2023, a +23.13% growth year-over-year.

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.